Antony Pfaffle

CIK 1368953 · Chief Scientific Officer · last filed 2017-02-08

Antony Pfaffle is a Chief Scientific Officer who has filed 22 SEC Form 4 insider transactions across 3 companies since 2010. The most recent filing, for CRMD, was dated Feb 8, 2017. Across all open-market trades the lifetime net is −$747.6K, making them a net seller over the disclosed history.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Disclosed Exposure

Companies

Total Filings

Lifetime Open-Market Net

-$747.6K

Charts

Trading activity, where the exposure sits, and each trade against the stock price.

CRMD price and trades

Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.

Shares held

Shares owned after each reported transaction on this company (direct holdings as reported).

Open-market buying and selling

by month

Dollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.

Exposure by company

latest

OfficerDirector10% owner* stale (no filing in 3 yrs)

Most recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.

Filer Profile

Reported Address

C/O INNOVIVE PHARMACEUTICALS, INC.
555 MADISON AVENUE, 25TH FLOOR
NEW YORK, NY 10022

Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.

Symbol	Role	Shares	Price	Disclosed Exposure	Lifetime OM Net	Filings	Latest Filed
CRMD	Chief Scientific Officer	0	$7.94	$0	-$748.1K	12	2017-02-08
CorMedix Inc. (CRMD.WS) Delisted	Interim Chief Medical Officer	16,725	—	—	$525	8	2015-02-26
CorMedix Inc. (CRMD.U) Delisted	Director	14,850	—	—	$0	1	2010-04-01

Recent Filings

22 filings

Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.

Filed	Symbol	Action	Net Shares	Net $	Link
2017-02-08	CRMD	Mixed	—	-$13.2K	EDGAR
2016-10-25	CRMD	Mixed	—	-$31.0K	EDGAR
2016-06-22	CRMD	Mixed	—	-$43.2K	EDGAR
2016-06-16	CRMD	Mixed	—	-$7.5K	EDGAR
2016-06-14	CRMD	Mixed	—	-$8.7K	EDGAR
2016-06-13	CRMD	Mixed	—	-$17.0K	EDGAR
2016-05-25	CRMD	Mixed	—	-$26.0K	EDGAR
2016-05-24	CRMD	Mixed	—	-$33.1K	EDGAR
2016-05-20	CRMD	Mixed	—	-$26.3K	EDGAR
2016-05-17	CRMD	Mixed	—	-$120.2K	EDGAR

Showing 1–10 of 22

Page 1 of 3 Next

Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.